BioWorld

Nov. 20, 2007

View Archived Issues

Celgene's $2.9B For Pharmion Nets Hematology, Cancer Lines

Celgene Corp. is acquiring Pharmion Corp. for $2.9 billion in a cash and stock deal that will expand the Summit, N.J.-based biotech's presence in the global hematology and oncology markets. (BioWorld Today) Read More

No Surprise As Onyx's Nexavar Wins Approval In Liver Cancer

Read More

Speedel, Novartis In Dispute On Flow Of Aliskiren Data

Read More

Clinic Roundup

Read More

Other News To Note

Read More

Financings Roundup

Read More